Health
AstraZeneca breast cancer drug misses primary goal in late-stage study
Camizestrant failed to outperform standard therapy in an advanced tumor trial, according to STAT.
The short version
- AstraZeneca announced that camizestrant failed to beat standard care in a pivotal clinical trial testing it as an initial therapy for advanced breast cancer.[STAT]
- The SERENA-4 trial evaluated the pill combined with another treatment in patients with ER-positive, HER2-negative advanced disease who had not undergone previous systemic therapy.[STAT]
- The drug recently secured accelerated U.S. regulatory approval under the brand Etcamah for patients harboring a specific drug-resistance mutation.[STAT]
Key facts
- AstraZeneca announced that camizestrant failed to meet its goal in a pivotal trial as a first-line treatment for advanced tumors.[STAT]
- Camizestrant combined with another medicine did not outperform standard care in preventing disease progression.[STAT]
- The SERENA-4 study evaluated participants with ER-positive, HER2-negative advanced cancer who had not received prior systemic treatment.[STAT]
- The medication earlier received accelerated U.S. approval as Etcamah for patients with a tumor mutation linked to drug resistance.[STAT]
What remains uncertain
- The extent to which the trial failure will limit future market expansion and additional indications for camizestrant remains unspecified.[STAT]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.